PT3039424T - Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo - Google Patents

Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo

Info

Publication number
PT3039424T
PT3039424T PT148409444T PT14840944T PT3039424T PT 3039424 T PT3039424 T PT 3039424T PT 148409444 T PT148409444 T PT 148409444T PT 14840944 T PT14840944 T PT 14840944T PT 3039424 T PT3039424 T PT 3039424T
Authority
PT
Portugal
Prior art keywords
methods
gene expression
same
kinase inhibitor
expression signatures
Prior art date
Application number
PT148409444T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Crown Bioscience Inc Taicang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crown Bioscience Inc Taicang filed Critical Crown Bioscience Inc Taicang
Publication of PT3039424T publication Critical patent/PT3039424T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT148409444T 2013-08-28 2014-08-28 Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo PT3039424T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2013082487 2013-08-28

Publications (1)

Publication Number Publication Date
PT3039424T true PT3039424T (pt) 2020-09-03

Family

ID=52587328

Family Applications (1)

Application Number Title Priority Date Filing Date
PT148409444T PT3039424T (pt) 2013-08-28 2014-08-28 Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo

Country Status (9)

Country Link
US (1) US11136625B2 (https=)
EP (1) EP3039424B1 (https=)
JP (1) JP6612232B2 (https=)
CN (1) CN105659085B (https=)
CY (1) CY1123415T1 (https=)
DK (1) DK3039424T3 (https=)
ES (1) ES2813877T3 (https=)
PT (1) PT3039424T (https=)
WO (1) WO2015031604A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3039424T (pt) 2013-08-28 2020-09-03 Crown Bioscience Inc Taicang Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo
WO2017110764A1 (ja) * 2015-12-24 2017-06-29 公益財団法人がん研究会 マルチキナーゼ阻害剤の有効性と安全性を予測する検査方法、検査キット、及びバイオマーカー
WO2020085936A1 (ru) * 2018-10-24 2020-04-30 Общество С Ограниченной Ответственностью "Онкобокс" Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки
EP3906031A4 (en) * 2019-01-02 2022-10-05 Zhejiang Crownmab Biotech Co. Ltd. CANCER TREATMENT USING A MULTI-TARGETED KINAS INHIBITOR IN COMBINATION WITH PROTEIN KINASES BIOMARKERS
CN111521810B (zh) * 2019-02-02 2024-06-21 中国科学院上海药物研究所 癌症患者根据脾酪氨酸激酶进行分层
CN111693707A (zh) * 2020-07-16 2020-09-22 首都医科大学附属北京朝阳医院 Rock激酶活性在辅助诊断血管炎患者中的应用
CN118345086B (zh) * 2024-04-22 2024-10-11 西部(重庆)科学城种质创制大科学中心 柑橘溃疡病抗性Cs7g24050基因及其编码蛋白与应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US6054270A (en) 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5871928A (en) 1989-06-07 1999-02-16 Fodor; Stephen P. A. Methods for nucleic acid analysis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
DE69233501T2 (de) 1991-11-22 2006-02-23 Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara Kombinatorische Strategien für die Polymersynthese
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CZ301689B6 (cs) 1999-11-05 2010-05-26 Astrazeneca Ab Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje
EP1255536B1 (en) 1999-12-22 2006-06-28 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine protein kinase
SI1255752T1 (sl) 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
EP1343782B1 (en) 2000-12-21 2009-05-06 SmithKline Beecham Corporation Pyrimidineamines as angiogenesis modulators
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP4982685B2 (ja) 2001-12-03 2012-07-25 バイエル、ファーマシューテイカルズ、コーポレイション ヒトがんを処置するための他の細胞毒剤又は細胞増殖抑制剤と組合わせたアリール尿素化合物
SE0104164L (sv) 2001-12-11 2003-06-12 Ericsson Telefon Ab L M Högspännings-mos-transistor
NO317200B1 (no) 2002-08-09 2004-09-13 Best Practice Deployment As System for trafikkopplaering i et kjoretoy
CN1911962A (zh) 2002-09-27 2007-02-14 奥里迪斯生物医学研究及开发有限责任公司 多肽与编码这些多肽的核酸和它们用于预防、诊断或治疗肝脏失调和上皮癌的用途
EP1639090A4 (en) * 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
PT2213661E (pt) 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
GB0411378D0 (en) 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
EP1907858A4 (en) * 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
BRPI0617488A2 (pt) 2005-10-21 2011-07-26 Bayer Healthcare Llc mÉtodo para a monitoraÇço do estado de uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente, mÉtodo de seleÇço de terapia para um paciente humano com uma doenÇa e mÉtodo de dignàstico para detectar uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
CA2627873A1 (en) 2005-10-31 2007-05-10 Scott Wilhelm Treatment of cancer with sorafenib
JP2009543797A (ja) 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド ナノ粒子ソラフェニブ製剤
KR20090071603A (ko) * 2006-09-19 2009-07-01 노파르티스 아게 Ｒａｆ 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커
US8609640B2 (en) 2007-07-25 2013-12-17 Eisai, Inc. Multikinase inhibitors for use in the treatment of cancer
US20090062368A1 (en) 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched sunitinib
US20090062347A1 (en) 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched axitinib
EP2195286A2 (en) 2007-09-10 2010-06-16 Cipla Limited Process for the preparation of a raf kinase inhibitor and intermediates for use in the process
EP2206775B1 (en) * 2007-09-26 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody
WO2009054004A2 (en) 2007-10-22 2009-04-30 Natco Pharma Limited Process for the preparation of sorafenib
EP2220071A2 (en) 2007-11-21 2010-08-25 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
US20100256392A1 (en) 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
WO2009104021A2 (en) 2008-02-21 2009-08-27 Generics [Uk] Limited Novel polymorphs and processes for their preparation
WO2009106825A1 (en) 2008-02-27 2009-09-03 Cipla Limited Polymorphs of sorafenib and salts thereof
WO2009111061A1 (en) 2008-03-06 2009-09-11 Sicor Inc. Process for the preparation of sorafenib and salts thereof
EP2098521A1 (en) 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
CA2720164A1 (en) 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
KR20110036055A (ko) 2008-06-23 2011-04-06 낫코 파마 리미티드 고순도의 수니티닙 및 이의 약학적으로 허용가능한 염의 개선된 제조 방법
WO2010011834A2 (en) 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
WO2010036796A1 (en) 2008-09-26 2010-04-01 Concert Pharmaceuticals, Inc. Pyridineamine derivatives
CA2704448A1 (en) 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Amorphous compositions of sunitinib base and l-malic acid
JP5439494B2 (ja) * 2008-10-21 2014-03-12 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
WO2010059742A1 (en) * 2008-11-18 2010-05-27 Collabrx, Inc. Individualized cancer treatment
WO2010135608A1 (en) * 2009-05-20 2010-11-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
JP2012533562A (ja) 2009-07-16 2012-12-27 グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド 治療法
US20120232102A1 (en) 2009-09-30 2012-09-13 Chun-Fang Xu Methods Of Administration And Treatment
JP2013505968A (ja) 2009-10-01 2013-02-21 シーエスエル、リミテッド フィラデルフィア染色体陽性白血病の治療方法
US20120245051A1 (en) * 2009-10-13 2012-09-27 Rimm David L Objective, quantitative method to predict histological subtype in non-small cell lung cancer
EP2490536A4 (en) 2009-10-23 2013-04-17 Glaxo Wellcome Mfg Pte Ltd COMPOSITION AND METHOD
TW201201808A (en) 2010-01-06 2012-01-16 Glaxo Wellcome Mfg Pte Ltd Treatment method
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
TW201206908A (en) 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
WO2011146458A1 (en) 2010-05-18 2011-11-24 Glaxo Wellcome Manufacturing Pte Ltd Method of administration and treatment
WO2012058780A1 (en) 2010-11-01 2012-05-10 Scinopharm (Kunshan) Biochemical Technology Co., Ltd. Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
US9150547B2 (en) 2010-11-29 2015-10-06 Hetero Research Foundation Process for the preparation of pazopanib using novel intermediate
WO2012088522A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
WO2012103060A1 (en) 2011-01-27 2012-08-02 Glaxo Wellcome Manufacturing Pte Ltd Method of administration and treatment
US20120214830A1 (en) * 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
CN102283836B (zh) 2011-06-27 2013-01-09 苏州大学附属第一医院 索拉非尼在制备治疗动脉瘤性自发性蛛网膜下腔出血后发生的早期脑损伤的药物中的应用
WO2013000909A1 (en) 2011-06-28 2013-01-03 Bayer Intellectual Property Gmbh Topical ophthalmological pharmaceutical composition containing sorafenib
CN103874770A (zh) * 2011-08-08 2014-06-18 卡里斯生命科学卢森堡控股有限责任公司 生物标志物组合物和方法
WO2013043529A1 (en) 2011-09-19 2013-03-28 Emory University Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
WO2013046133A1 (en) 2011-09-30 2013-04-04 Pfizer Inc. Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
US20140322166A1 (en) * 2011-12-12 2014-10-30 Stc. Unm Gene expression signatures for detection of underlying philadelphia chromosome-like (ph-like) events and therapeutic targeting in leukemia
WO2013138522A2 (en) * 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
PT3039424T (pt) 2013-08-28 2020-09-03 Crown Bioscience Inc Taicang Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo

Also Published As

Publication number Publication date
US11136625B2 (en) 2021-10-05
JP6612232B2 (ja) 2019-11-27
ES2813877T3 (es) 2021-03-25
US20160208328A1 (en) 2016-07-21
EP3039424A1 (en) 2016-07-06
CN105659085A (zh) 2016-06-08
JP2016528914A (ja) 2016-09-23
WO2015031604A1 (en) 2015-03-05
EP3039424A4 (en) 2017-03-29
CN105659085B (zh) 2018-12-07
EP3039424B1 (en) 2020-07-29
CY1123415T1 (el) 2021-12-31
DK3039424T3 (da) 2020-08-31

Similar Documents

Publication Publication Date Title
EP2965174A4 (en) INTERACTION OF MULTIPLE PERCEPTIVE DETECTION INPUTS
GB2537262B (en) Temperature sensing using distributed acoustic sensing
GB2517212B (en) A Computer Generated Emulation of a subject
IL241370A0 (en) Carm1 inhibitors and their uses
RS63939B1 (sr) Inhibitori lizin specifične demetilaze-1
SMT201900136T1 (it) Inibitori di gsk3 e loro metodi di uso
EP2904115A4 (en) BIOMARKERS AND METHODS FOR PREDICTING RESPONSE TO INHIBITORS AND USES THEREOF
ZA201702252B (en) A selective inhibitor of prosphatidylinositol 3-kinase-gamma
PL2997117T3 (pl) Zastosowanie estru
PT3039424T (pt) Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo
EP2981920A4 (en) Detection of user behavior using time series modeling
ZA201600927B (en) Structural assembly and method of assembly thereof
IL246258A0 (en) Synthesis of an enantiomer of progesterone and its intermediates
ZA201508288B (en) Methods of synthesis of ingenol and intermediates thereof
ZA201508010B (en) Inhibitors of metastasis
PT3022290T (pt) Estirpe de algas modificadas e método de acumulação de triacilglicerol usando a referida estirpe
GB2510569B (en) Improvements relating to abandonment and recovery of pipelines
ZA201506787B (en) Synthesis of ent-progesterone and intermediates thereof
GB201312311D0 (en) Uses of enzyme inhibitors
GB201313826D0 (en) Predicting of physical training response
IL236717A0 (en) A compound constituting a multi-detector array and methods for use
GB201320835D0 (en) HIF inhibitors
GB201305503D0 (en) Inhibitor
GB201307906D0 (en) Corrosion inhibitor